drugset / Trial / NCT05670379

Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

NCT05670379

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.

Timeline

Start
2024-12-20
Primary completion
2025-08-21
Completion
2025-08-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exenatide Peptide 52 ug Subcutaneous
Comparator Exenatide Peptide 2 mg Subcutaneous
Comparator Semaglutide Peptide 1 mg Subcutaneous